GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chugai Pharmaceutical Co Ltd (OTCPK:CHGCF) » Definitions » Net-Net Working Capital

Chugai Pharmaceutical Co (Chugai Pharmaceutical Co) Net-Net Working Capital : $3.35 (As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Chugai Pharmaceutical Co Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Chugai Pharmaceutical Co's Net-Net Working Capital for the quarter that ended in Mar. 2024 was $3.35.

The industry rank for Chugai Pharmaceutical Co's Net-Net Working Capital or its related term are showing as below:

CHGCF's Price-to-Net-Net-Working-Capital is ranked worse than
57.82% of 422 companies
in the Drug Manufacturers industry
Industry Median: 7.78 vs CHGCF: 9.66

Chugai Pharmaceutical Co Net-Net Working Capital Historical Data

The historical data trend for Chugai Pharmaceutical Co's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chugai Pharmaceutical Co Net-Net Working Capital Chart

Chugai Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net-Net Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.94 2.37 2.63 2.65 3.41

Chugai Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.87 3.02 2.93 3.41 3.35

Competitive Comparison of Chugai Pharmaceutical Co's Net-Net Working Capital

For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chugai Pharmaceutical Co's Price-to-Net-Net-Working-Capital Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Chugai Pharmaceutical Co's Price-to-Net-Net-Working-Capital falls into.



Chugai Pharmaceutical Co Net-Net Working Capital Calculation

Chugai Pharmaceutical Co's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2023 is calculated as

Net-Net Working Capital(A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(5132.479+0.75 * 2214.812+0.5 * 1899.411-2131.989
-0-0)/1645.31
=3.41

Chugai Pharmaceutical Co's Net-Net Working Capital (NNWC) per share for the quarter that ended in Mar. 2024 is calculated as

Net-Net Working Capital(Q: Mar. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(5103.278+0.75 * 1599.728+0.5 * 1846.78-1706.844
-0-0)/1645.38
=3.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


Chugai Pharmaceutical Co  (OTCPK:CHGCF) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


Chugai Pharmaceutical Co Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Chugai Pharmaceutical Co's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Chugai Pharmaceutical Co (Chugai Pharmaceutical Co) Business Description

Traded in Other Exchanges
Address
1-1 Nihonbashi-Muromachi 2-Chome, Nihonbashi Mitsui Tower (Reception15F), Chuo-ku, Tokyo, JPN, 103-8324
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding Ltd, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and tocilizumab for treating rheumatoid arthritis and COVID-19.

Chugai Pharmaceutical Co (Chugai Pharmaceutical Co) Headlines